Breaking News

Tweet TWEET

European Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - 2013 Report

European Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - 2013
Report

Dublin, Nov. 4, 2013 (GLOBE NEWSWIRE) -- Research and Markets
(http://www.researchandmarkets.com/research/3lndkv/european_nuclear) has
announced the addition of the "European Nuclear Medicine/Radiopharmaceuticals
& Stable Isotopes Market - Trends & Forecast to 2017" report to their
offering.

The European radioisotopes market was valued at $1.1 billion in 2012 and is
poised to reach $1.6 billion in 2017 at a CAGR of 6.8%.

A study conducted by Organization for Economic Co-operation and Development
(OECD) estimates that Tc-99m diagnostic procedures are expected to increase by
15% to 20% in mature markets such as Europe, and other developed regions
between 2010 and 2030. Radiopharmaceuticals in neurological applications such
as Alzheimer's disease, Parkinson's disease, and dementia are also being
preferred by practitioners besides conventional treatment. Further, upcoming
radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for
clinical applications. The scheduled shutdown of the NRU reactor in 2016 and
OSIRIS in France in 2018 is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications.
Since conventional treatment procedures of cancer, surgery and chemotherapy
have significant side effects, radioisotopes are being preferred by medical
practitioners due to minimum or no side effects. The radiopharmaceutical
therapy market is expected to grow significantly with the launch of the
much-desired Alpharadin (Ra-223) in the near future. This isotope has
tremendous potential to take up market share of beta emitters and
brachytherapy.
The radioisotope and stable isotope markets have been segmented according to
the type of isotope, and applications. Both of these markets are broken down
into segments and sub-segments, providing exhaustive value analysis for the
years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively
analyzed at a granular level by geography (North America, Europe, Asia, and
Rest of the World) to provide in-depth information on the European scenario.

Key Topics Covered:

1 Key Take-Aways

2 Executive Summary

3 Market Overview

4 European Radiopharmaceuticals Market, By Isotope

5 European Radiopharmaceuticals Market,By Application/Indication

6 European Enriched Stable Isotopes Market

7 Geographic Analysis

8 Competitive Landscape

9 Company Profiles

Companies Mentioned

  *Bracco Imaging
  *Cambridge Isotope Laboratories
  *Cardinal Health
  *Covidien
  *Eczacibasi-Monrol
  *Fujifilm Holdings
  *Ge Healthcare (Subsidiary Of General Electric Company)
  *Iba Group
  *Isotec
  *Lantheus Medical Imaging
  *Nordion
  *Ntp Radioisotopes
  *Petnet Solutions
  *Rotem Industries
  *Taiyo Nippon Sanso Corporation
  *Urenco Limited

For more information visit
http://www.researchandmarkets.com/research/3lndkv/european_nuclear

About Research and Markets

Research and Markets is the world's leading source for international market
research reports and market data. We provide you with the latest data on
international and regional markets, key industries, the top companies, new
products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Research and Markets logo
 
Press spacebar to pause and continue. Press esc to stop.